Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Dance Biopharm Forms China Inhaled Insulin JV with Harmony Asset

publication date: Oct 16, 2013
Dance Biopharm, a US biotech, will form a joint venture with Harmony Asset of Hong Kong to jointly develop Dance’s second-generation inhaled insulin, a clinical-stage product. The JV will own rights to Adagio™ in China and other Asian countries with the exception of Japan. Harmony will be responsible for most of the development expenses in each country. It will receive proportionate ownership in those territories depending on its contribution. Dance said the JV will expedite its China efforts, which will include more partnerships. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital